Answers from the Lab Mayo Clinic Laboratories
-
- Health & Fitness
-
A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.
-
Get to Know the DLMP Chair: Eric Hsi, M.D.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Eric Hsi, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic.
Their discussion includes:
Dr. Hsi’s experience in the field of pathology and what he is looking forward to working on as the new chair of the Department of Laboratory Medicine and Pathology (DLMP) at Mayo Clinic.Some common challenges facing laboratory professionals today and ways to overcome them.Advancements and trends in pathology and staying current with new developments.Words of advice for pathologists who are beginning their careers. -
Oral fluid offers an alternative specimen for controlled substance monitoring: Paul Jannetto, Ph.D.
Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.
(00:32) Can you tell us a little bit about yourself and your background?
(01:46) Can you please provide an overview of laboratory testing for substance use disorders and specifically Mayo Clinic's new oral fluid controlled substance monitoring option?
(03:47) Which patients should have this testing and when should it be performed?
(05:16) What alternative test options are available and how do these compare?
(06:31) How are the results used in patient care? -
FDA Issues Final Rule to Regulate LDTs: Bill Morice, M.D., Ph.D.
In this special episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the final rule issued by the U.S. Food and Drug Administration (FDA) on April 29, 2024, to make explicit its plan to regulate laboratory-developed tests (LDT) as medical devices under the Federal Food, Drug, and Cosmetic Act.
Their discussion includes:
Highlighting key points, exceptions, and the phased implementation plan of the final rule.How the FDA’s final rule compares to its proposed rule from last year.How the news may impact laboratories, health systems, health agencies, and manufacturers.Uncertainties that still remain regarding the future of laboratory-developed tests. -
The Growing Crisis of Antimicrobial Resistance: Robin Patel, M.D.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Robin Patel, M.D.,director of the Infectious Diseases Research Laboratory and co-director of the Bacteriology Laboratory at Mayo Clinic. They discuss antimicrobial resistance and why it’s a major global health concern.
Specific topics of discussion include:
Background information on antimicrobial resistance and why it is a growing threat to global health.What is being done to address the problem, and Dr. Patel’s work as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria.How laboratorians and pathologists can advocate for continued action on antimicrobial resistance. -
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the condition, which severely impacts multiple organs and blood.
(00:31) Could you please provide a little bit about yourself and your background?
(01:30) Would you please share a brief overview of the UBA1Q assay?
(02:13) Would you provide an overview of VEXAS syndrome?
(05:30) When is this testing recommended during care for patients who have a suspected inflammatory condition or VEXAS syndrome?
(06:38) What advantage does this assay provide over other methodologies?
(10:13) Could you share further why diagnosis is so important for these patients?
(12:40) Is there anything else you'd like to comment about the assay? -
Alzheimer’s Disease and Testing Innovations: Bill Morice, M.D., Ph.D.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss testing innovations for Alzheimer’s disease and cognitive impairments, and how laboratorians can responsibly help shape the future of healthcare.
Their discussion includes:
The latest news about the U.S. Food and Drug Administration’s (FDA) proposed rule around regulating lab-developed tests.New testing innovations for Alzheimer’s disease and cognitive impairments, including Mayo Clinic Laboratories’ plasma biomarker testing for Alzheimer’s disease. The importance of being responsible lab stewards and working closely with clinicians to understand how different testing approaches drive decision-making in healthcare settings.